Alivus Life Sciences Statistics
Total Valuation
Alivus Life Sciences has a market cap or net worth of INR 117.44 billion. The enterprise value is 113.13 billion.
Market Cap | 117.44B |
Enterprise Value | 113.13B |
Important Dates
The last earnings date was Friday, October 25, 2024.
Earnings Date | Oct 25, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Alivus Life Sciences has 122.53 million shares outstanding. The number of shares has increased by 0.28% in one year.
Current Share Class | n/a |
Shares Outstanding | 122.53M |
Shares Change (YoY) | +0.28% |
Shares Change (QoQ) | +0.17% |
Owned by Insiders (%) | 0.00% |
Owned by Institutions (%) | 4.53% |
Float | 30.64M |
Valuation Ratios
The trailing PE ratio is 27.81 and the forward PE ratio is 21.64. Alivus Life Sciences's PEG ratio is 1.40.
PE Ratio | 27.81 |
Forward PE | 21.64 |
PS Ratio | 5.33 |
PB Ratio | 4.63 |
P/TBV Ratio | 4.66 |
P/FCF Ratio | 44.32 |
P/OCF Ratio | n/a |
PEG Ratio | 1.40 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 18.68, with an EV/FCF ratio of 42.69.
EV / Earnings | 26.71 |
EV / Sales | 5.13 |
EV / EBITDA | 18.68 |
EV / EBIT | 20.50 |
EV / FCF | 42.69 |
Financial Position
The company has a current ratio of 4.52, with a Debt / Equity ratio of 0.01.
Current Ratio | 4.52 |
Quick Ratio | 2.81 |
Debt / Equity | 0.01 |
Debt / EBITDA | 0.03 |
Debt / FCF | 0.06 |
Interest Coverage | 381.48 |
Financial Efficiency
Return on equity (ROE) is 17.18% and return on invested capital (ROIC) is 13.90%.
Return on Equity (ROE) | 17.18% |
Return on Assets (ROA) | 11.43% |
Return on Capital (ROIC) | 13.90% |
Revenue Per Employee | 10.95M |
Profits Per Employee | 2.10M |
Employee Count | 2,014 |
Asset Turnover | 0.73 |
Inventory Turnover | 1.52 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +48.51% in the last 52 weeks. The beta is 0.16, so Alivus Life Sciences's price volatility has been lower than the market average.
Beta (5Y) | 0.16 |
52-Week Price Change | +48.51% |
50-Day Moving Average | 1,064.78 |
200-Day Moving Average | 950.73 |
Relative Strength Index (RSI) | 32.10 |
Average Volume (20 Days) | 118,580 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Alivus Life Sciences had revenue of INR 22.05 billion and earned 4.24 billion in profits. Earnings per share was 34.46.
Revenue | 22.05B |
Gross Profit | 11.73B |
Operating Income | 5.52B |
Pretax Income | 5.68B |
Net Income | 4.24B |
EBITDA | 6.03B |
EBIT | 5.52B |
Earnings Per Share (EPS) | 34.46 |
Balance Sheet
The company has 4.46 billion in cash and 159.77 million in debt, giving a net cash position of 4.30 billion or 35.12 per share.
Cash & Cash Equivalents | 4.46B |
Total Debt | 159.77M |
Net Cash | 4.30B |
Net Cash Per Share | 35.12 |
Equity (Book Value) | 25.38B |
Book Value Per Share | 207.20 |
Working Capital | 16.32B |
Cash Flow
In the last 12 months, operating cash flow was 4.17 billion and capital expenditures -1.52 billion, giving a free cash flow of 2.65 billion.
Operating Cash Flow | 4.17B |
Capital Expenditures | -1.52B |
Free Cash Flow | 2.65B |
FCF Per Share | 21.63 |
Margins
Gross margin is 53.21%, with operating and profit margins of 25.03% and 19.21%.
Gross Margin | 53.21% |
Operating Margin | 25.03% |
Pretax Margin | 25.76% |
Profit Margin | 19.21% |
EBITDA Margin | 27.34% |
EBIT Margin | 25.03% |
FCF Margin | 12.02% |
Dividends & Yields
This stock pays an annual dividend of 22.50, which amounts to a dividend yield of 2.35%.
Dividend Per Share | 22.50 |
Dividend Yield | 2.35% |
Dividend Growth (YoY) | 314.29% |
Years of Dividend Growth | 1 |
Payout Ratio | 65.10% |
Buyback Yield | -0.28% |
Shareholder Yield | 2.07% |
Earnings Yield | 3.60% |
FCF Yield | 2.26% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | n/a |